title: [Effects of cardiovascular therapy on risk of the development of ischemia and myocardial infarction in the postoperative period in cancer patients with ischemic heart diseases].
abstract: Analysis of 636 surgical interventions for malignant tumors in 576 chronic coronary patients showed that beta-blockers decreased the relative risk of ischemia and myocardial infarction during the postoperative period. Calcium antagonists verapamil and dihydropyridines also essentially decreased the probability of myocardial infarction and less so of myocardial ischemia. Antiischemic effect of nitrates was insignificant, and they increased the risk of myocardial infarction. Antioxidants did not prevent ischemia but significantly decreased the risk of infarction. Therapy with non-fractionated heparin involved the risk of ischemia and myocardial infarction. The causes of low cardioprotective effects of nitrates and heparin can be explained by the discontinuation syndrome, which increases the risk of exacerbation of coronary disease during the postoperative period.
authors.forename: A E
authors.initials: AE
authors.lastname: Stetsenko
authors.forename: V L
authors.initials: VL
authors.lastname: Kassil'
authors.forename: T I
authors.initials: TI
authors.lastname: Ushakova
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D004095:Dihydropyridines / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000517:prevention & control*; D017202:Myocardial Ischemia / Q000150:complications* / Q000517:prevention & control*; D009369:Neoplasms / Q000601:surgery*; D009566:Nitrates / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control*; D012307:Risk Factors; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014700:Verapamil / Q000627:therapeutic use*
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000925:Anticoagulants; D000975:Antioxidants; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D005343:Fibrinolytic Agents; D009566:Nitrates; D014665:Vasodilator Agents; C038806:1,4-dihydropyridine; D006493:Heparin; D014700:Verapamil